Intermittent versus continuous androgen deprivation in prostate cancer

New England Journal of Medicine

Volumn 368, Issue 14, 2013, Pages 1314-1325

  Hussain, Maha ^a   Tangen, Catherine M ^b   Berry, Donna L ^d   Higano, Celestia S ^c   Crawford, E David ^e   Liu, Glenn ^f   Wilding, George ^f   Prescott, Stephen ^g   Sundaram, Subramanian Kanaga ^h   Small, Eric Jay ⁱ   Dawson, Nancy Ann ^j   Donnelly, Bryan J ^k   Venner, Peter M ^l   Vaishampayan, Ulka N ^m   Schellhammer, Paul F ⁿ   Quinn, David I ^o   Raghavan, Derek ^p   Ely, Benjamin ^b   Moinpour, Carol M ^q   Vogelzang, Nicholas J ^r,t   Thompson, Ian M ^s   more..

^a UNIVERSITY OF MICHIGAN   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF WISCONSIN   (United States)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h MID YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j GEORGETOWN UNIVERSITY   (United States)

^k Prostate Cancer Center   (Canada)

^l CROSS CANCER INSTITUTE   (Canada)

^m WAYNE STATE UNIVERSITY   (United States)

ⁿ Urology of Virginia   (United States)

^o UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^p LEVINE CANCER INSTITUTE   (United States)

^q Fred Hutchinson Cancer Research Center   (United States)

^r McKesson Specialty Health   (United States)

^s University of Texas Health Science Center at San Antonio   (United States)

^t NV   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; GOSERELIN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OVERALL SURVIVAL; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84875793215     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1212299     Document Type: Article

References (25)

1. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321:419-24. [Erratum, N Engl J Med 1989; 321:1420.] (Pubitemid 19211484)
2. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339: 1036-42. (Pubitemid 28457865)
3. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488-90. (Pubitemid 39315314)
4. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011;29:3651-8.
5. Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990;50:2275-82. (Pubitemid 20134481)
6. Trachtenberg J. Experimental treatment of prostatic cancer by intermittent hormonal therapy. J Urol 1987;137:785-8. (Pubitemid 17048685)
7. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 1993;71:2782-90. (Pubitemid 23120055)
8. Bhandari MS, Crook J, Hussain M. Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 2005;23:8212-8. (Pubitemid 46211557)
9. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995;45:839-44.
10. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996;48: 800-4. (Pubitemid 26409365)
11. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
12. Moinpour CM, Hayden KA, Thompson IM, Feigl P, Metch B. Quality of life assessment in Southwest Oncology Group trials. Oncology (Williston Park) 1990; 4(5):79-84.
13. Moinpour CM, Savage MJ, Troxel A, et al. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998;90:1537-44. (Pubitemid 28535718)
14. Moinpour CM, Sawyers Triplett J, McKnight B, et al. Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psychooncology 2000;9: 340-54.
15. Moinpour CM, Savage M, Hayden KA, Sawyers J, Upchurch C. Quality of life assessment in cancer clinical trials. In: Dimsdale JE, Baum A, eds. Quality of life in behavioral medicine research. Hillsdale, NJ: Lawrence Erlbaum Associates, 1995:79-95.
16. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31:247-63.
17. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
18. Lin DW, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale- based residuals. Biometrika 1993; 80:557-72.
19. Pauler DK, McCoy S, Moinpour C. Pattern mixture models for longitudinal quality of life studies in advanced stage disease. Stat Med 2003;22:795-809. (Pubitemid 36266967)
20. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006;295:1152-60. [Erratum, JAMA 2006;296:1842.] (Pubitemid 43352345)
21. Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009;55:1269-77.
22. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012;367:895-903. [Erratum, N Engl J Med 2012;367:2262.]
23. de Leval J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1: 163-71. (Pubitemid 37012397)
24. Gruca D, Bacher P, Tunn U. Safety and tolerability of intermittent androgen deprivation therapy: a literature review. Int J Urol 2012;19:614-25.
25. Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol 2012;187:2074-81.